Signature HealthCARE Facilities Ranked as America’s Best in Newsweek 2022 Survey
January 25, 2022 13:17 ET
|
Signature Healthcare
Louisville, Ky., Jan. 25, 2022 (GLOBE NEWSWIRE) -- In the ever-changing environment of long-term care during our nation’s on-going pandemic, the balance between enduring and thriving is a daunting...
Pfizer und BioNTech beginnen klinische Studie zu Omikron-basiertem COVID-19-Impfstoff bei Erwachsenen im Alter von 18-55 Jahren
January 25, 2022 06:45 ET
|
BioNTech SE
Die ersten Teilnehmer erhielten im Rahmen der klinischen Studie den Omikron-basierten Impfstoffkandidaten als Impfserie mit zwei Dosen oder als Auffrischungsimpfung NEW YORK und MAINZ, Deutschland,...
Pfizer and BioNTech Initiate Study to Evaluate Omicron-Based COVID-19 Vaccine in Adults 18 to 55 Years of Age
January 25, 2022 06:45 ET
|
BioNTech SE
First participants enrolled in clinical trial received Omicron-based vaccine candidate as a two-dose primary series and as a booster dose NEW YORK and MAINZ, GERMANY, JANUARY 25, 2022 — Pfizer Inc....
Everstream Analytics Supply Chain Risk Solutions Now Available on Oracle Cloud Marketplace
January 24, 2022 10:00 ET
|
Everstream Analytics
SAN MARCOS, Calif., Jan. 24, 2022 (GLOBE NEWSWIRE) -- Everstream Analytics, a leading provider of Supply Chain Risk Analytics and a member of Oracle PartnerNetwork (OPN), today announced that...
SAB Biotherapeutics Reports Positive Phase 2 Virology Data Demonstrating SAB-185 Met Criteria for Advancement to Phase 3 in NIH ACTIV-2 Trial for Treatment of COVID-19
January 24, 2022 06:00 ET
|
SAB Biotherapeutics, Inc.
SAB-185 is being evaluated in Phase 3 NIH-Sponsored ACTIV-2 COVID trial of high-risk patients following positive DSMB review of interim Phase 2 safety and efficacy data in September More than 700...
Given the Current Testing Restraints, Luxor Scientific Reiterates Excess Capacity for COVID-19 Testing
January 19, 2022 14:02 ET
|
Luxor Scientific, LLC.
GREENVILLE, S.C., Jan. 19, 2022 (GLOBE NEWSWIRE) -- Luxor Scientific, a full-service clinical testing laboratory that provides laboratory services nationally and for individuals within the region,...
Achiko AG Announces Feature Article on “How We Get Back to Normal” with its AptameX™ Covid-19 Rapid Test Technology
January 18, 2022 07:30 ET
|
Achiko AG
ZURICH, Switzerland, Jan. 18, 2022 (GLOBE NEWSWIRE) -- Achiko AG (OTCQB: ACHKF; SIX: ACHI; ISIN CH0522213468) (“Achiko”, the “Company”) is pleased to announce a feature article in The Jakarta Post:...
Achiko AG Reports Breakthrough Calibration Results for its AptameX™ Covid-19 Rapid Test Technology
January 14, 2022 07:30 ET
|
Achiko AG
AptameX™ Covid-19 rapid calibration successfully classified 100% of results indicatinga likely > 97% Sensitivity and > 97% Specificity result in the first-generation test kits.Results were...
Adagio Therapeutics resume actividad neutralizante de ADG20 contra variantes de SARS-CoV-2 y describe iniciativas para abordar la variante ómicron
January 13, 2022 19:30 ET
|
Adagio Therapeutics, Inc.
Publicaciones recientes de varios laboratorios independientes muestran que ADG20 tiene actividad neutralizante con potencia comparable a otros anticuerpos que retienen actividad contra la variante...
Adagio Therapeutics legt zusammenfassende Ergebnisse zur neutralisierenden Wirkung von ADG20 gegenüber SARS-CoV-2-Varianten vor und stellt Initiativen zur Bekämpfung von Omikron vor
January 13, 2022 19:30 ET
|
Adagio Therapeutics, Inc.
Aktuelle Veröffentlichungen verschiedener unabhängiger Labore bestätigen, dass die neutralisierende Wirkung von ADG20 mit anderen Antikörpern vergleichbar ist, die die Aktivität gegen Omikron...